Copyright © 1997 by the European Society of Cardiology.
© 1997 The European Society of Cardiology
Streptokinase vs alteplase in massive pulmonary embolism
A randomized trial assessing right heart haemodynamics and pulmonary vascular obstruction
*Departement de Cardiologie, Hopital Universitaire Saint-Jacques Besançon, France
Departement de Cardiologie, Hopital Universitaire Côte de Nacre Caen, France
revised 30 August 1996; accepted 9 September 1996.
Correspondence: J. P. Bassand, Departement de Cardiologie, Hopital Universitaire Saint-Jacques, 25 000 Besançon, France
Abstract
OBJECTIVE: The aim of the study was to test the efficacy of recombinant tissue plasminogen activator and streptokinase in massive pulmonary embolism, the primary endpoints being haemodynamic improvement and thrombus lysis, and the secondary endpoints efficacy and safety.
DESIGN: Fifty patients with massive pulmonary embolism were randomly allocated either to a 100 mg 2 h infusion of recombinant tissue plasminogen activator followed by a 20 IU.kg–1.h–1 infusion of heparin, or to a 100 000 IU.h–1 12 h infusion of streptokinase after a initial bolus of 250 000 IU over 15 min, followed by heparin infusion of 10 IU.kg–1.h–1. Total pulmonary resistance and right ventricular ejection fraction were monitored over a 12 h period. Pulmonary vascular obstruction was assessed at 24 to 48 h and 10 days after thrombolytic therapy.
RESULTS: Thrombolysis occurred more rapidly with recombinant tissue plasminogen activator than with streptokinase, but without any significant difference in terms of right heart haemodynamics at 12 h or in improvement of pulmonary vascular obstruction at 24–48 h or at 10 days. There was no significant difference in bleeding complication rates and no patients suffered intracranial haemorrhage.
CONCLUSION: These results proved that, when the full dose of streptokinase has been given over 12 h, its efficacy is as good as that of 2 h of recombinant tissue plasminogen. A further trial aimed at comparing recombinant tissue plasminogen activator and streptokinase infused over a 2 h period is needed to determine whether a similar efficacy can be obtained.
Key Words: Massive pulmonary embolism • thrombolysis • streptokinase • rt-PA • right ventricular function • total pulmonary resistance
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. E. A. Burns and A. McLaren A critical review of thromboembolic complications associated with central venous catheters: [Une synthese critique des complications thromboemboliques associees aux catheters veineux centraux] Can J Anesth, August 1, 2008; 55(8): 532 - 541. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Kearon, S. R. Kahn, G. Agnelli, S. Goldhaber, G. E. Raskob, and A. J. Comerota Antithrombotic Therapy for Venous Thromboembolic Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 454S - 545S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Capstick and M. T. Henry Efficacy of thrombolytic agents in the treatment of pulmonary embolism Eur. Respir. J., November 1, 2005; 26(5): 864 - 874. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T Harris and S Meek When should we thrombolyse patients with pulmonary embolism? A systematic review of the literature Emerg. Med. J., November 1, 2005; 22(11): 766 - 771. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. R. Buller, G. Agnelli, R. D. Hull, T. M. Hyers, M. H. Prins, and G. E. Raskob Antithrombotic Therapy for Venous Thromboembolic Disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 401S - 428S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Kreit The Impact of Right Ventricular Dysfunction on the Prognosis and Therapy of Normotensive Patients With Pulmonary Embolism Chest, April 1, 2004; 125(4): 1539 - 1545. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 British Thoracic Society guidelines for the management of suspected acute pulmonary embolism Thorax, June 1, 2003; 58(6): 470 - 483. [Full Text] [PDF]
|
|
|
|
 |
|
 G. S. Ahearn, D. Hadjiliadis, J. A. Govert, and V. F. Tapson Massive Pulmonary Embolism During Pregnancy Successfully Treated With Recombinant Tissue Plasminogen Activator: A Case Report and Review of Treatment Options Arch Intern Med, June 10, 2002; 162(11): 1221 - 1227. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Schmitz-Rode, U. Janssens, S. H. Duda, C. M. Erley, and R. W. Gunther Massive pulmonary embolism: percutaneous emergency treatment by pigtail rotation catheter J. Am. Coll. Cardiol., August 1, 2000; 36(2): 375 - 380. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Arcasoy and J. W. Kreit Thrombolytic Therapy of Pulmonary Embolism: A Comprehensive Review of Current Evidence Chest, June 1, 1999; 115(6): 1695 - 1707. [Abstract] [Full Text] [PDF]
|
|